Full Press Release Details
Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
New Jersey, April 8, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health
information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone,
the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for
their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes
its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which
we believe should lead to a scaling up of the antigens.
Kundu, Co-Founder and Managing Director at Premas
Biotech, commented, "We are happy to announce our success in expressing all three antigens. We continue to believe that
the immune system is better served with three shots on goal and our inclusion of the S, E, and M antigens together should enhance
the efficacy of our vaccine candidate. We are also pleased with the expedited nature of our milestones thus far, which is a positive
step towards our goal to reach clinical trials."
Schreiber, Executive Chairman of Akers, stated, "We are now halfway through our four-milestone plan that we believe will
allow us to commence clinical trials. Our partnership with Premas is executing very well and we look forward to sharing the next
milestones as they occur in the weeks to come."
Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic
& vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation.
Besides D-CryptTM the difficult to express proteins expression platform, Premas' leading technologies include
Axtex-4D : an ex-vivo tissueoid generation platform and C-Qwence : a fully human naive India based scFv antibody
library. Further information is available on the Company's website: www.premasbiotech.com
email: contact@premasbiotech.com
Akers Biosciences Inc.
Biosciences is pursuing the development of a newly acquired license to a coronavirus vaccine candidate. In addition, the company
develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health related information
directly to the patient or clinician in a timely and cost-efficient manner. Akers has previously announced that that it had identified
the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers' existing facility
and its core competencies.
information on the company and its products can be found at www.akersbio.com.
in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are
not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include any risks detailed from time to time in Akers'
reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K. Forward-looking statements may be identified by terms such as "may," "will," "expects,"
"plans," "intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although Akers believes the expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. Akers
does not have any obligation to update these forward-looking statements other than as required by law.
Maas, Managing Partner